Andrew R Pettitt

Andrew R Pettitt

UNVERIFIED PROFILE

Are you Andrew R Pettitt?   Register this Author

Register author
Andrew R Pettitt

Andrew R Pettitt

Publications by authors named "Andrew R Pettitt"

Are you Andrew R Pettitt?   Register this Author

43Publications

479Reads

Central nervous system plasmablastic lymphoma evolving from polyclonal plasmacytosis.

Br J Haematol 2018 Nov 9;183(3):345. Epub 2018 Jul 9.

Haemato-oncology Diagnostic Service, Liverpool Clinical Laboratories, Liverpool, UK.

View Article
November 2018

Delineating the distinct role of AKT in mediating cell survival and proliferation induced by CD154 and IL-4/IL-21 in chronic lymphocytic leukemia.

Oncotarget 2017 Nov 7;8(61):102948-102964. Epub 2017 Nov 7.

Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.

View Article
November 2017

Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia.

Nat Commun 2017 02 6;8:14175. Epub 2017 Feb 6.

Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA.

View Article
February 2017

Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia.

Mol Cell Proteomics 2015 Apr 2;14(4):933-45. Epub 2015 Feb 2.

From the ‡Department of Molecular and Clinical Cancer Medicine, ¶Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool L7 8XP, UK

View Article
April 2015

Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.

J Immunol 2015 Mar 28;194(5):2439-46. Epub 2015 Jan 28.

Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3GA, United Kingdom.

View Article
March 2015

Selective IAP inhibition results in sensitization of unstimulated but not CD40-stimulated chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis.

Pharmacol Res Perspect 2014 Dec 1;2(6):e00081. Epub 2014 Sep 1.

Department of Molecular and Clinical Cancer Medicine, University of Liverpool Liverpool, United Kingdom ; Royal Liverpool & Broadgreen University Hospitals NHS Trust Liverpool, United Kingdom.

View Article
December 2014

Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach.

Br J Haematol 2014 Nov 30;167(4):565-9. Epub 2014 Jun 30.

Department of Haematology, Academic Medical Centre, Amsterdam, The Netherlands; Laboratory of Exp. Immunology, Academic Medical Centre, Amsterdam, The Netherlands.

View Article
November 2014

Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia.

Br J Haematol 2014 Nov 18;167(3):346-55. Epub 2014 Jul 18.

Department of Haematology, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.

View Article
November 2014

Motility and trafficking in B-cell non-Hodgkin's lymphoma (Review).

Int J Oncol 2014 Jul 23;45(1):5-12. Epub 2014 Apr 23.

Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3GA, UK.

View Article
July 2014

Pharmacogenetics in the treatment of chronic lymphocytic leukemia: what does the future hold?

Pharmacogenomics 2014 May;15(7):897-900

Department of Haematology, Royal Liverpool & Broadgreen University Hospitals Trust, Liverpool, UK.

View Article
May 2014

Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.

J Clin Oncol 2014 Apr 17;32(12):1236-41. Epub 2014 Mar 17.

Peter Hillmen, Abraham Varghese, and Andy Rawstron, St James's Institute of Oncology; Dena Cohen, University of Leeds, Leeds; John G. Gribben, Barts and the London School of Medicine; Claire E. Dearden, Royal Marsden Hospital; Amit Nathwani, University College London, London; George A. Follows, Addenbrooke's Hospital, Cambridge; Donald Milligan, Heartlands Hospital, Birmingham; Hazem A. Sayala, Hull and East Yorkshire Hospitals, Hull; Paul Moreton, Pinderfields General Hospital, Wakefield; David G. Oscier, Royal Bournemouth Hospital, Bournemouth; Daniel B. Kennedy, Leicester Royal Infirmary, Leicester; Andrew R. Pettitt, Royal Liverpool and Broadgreen University Hospitals National Health Service Trust, Liverpool; Christopher F.E. Pocock, East Kent Hospitals, Canterbury, United Kingdom; and Stephan Oertel, F. Hoffmann-La Roche, Basel, Switzerland.

View Article
April 2014

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

N Engl J Med 2014 Mar 22;370(11):997-1007. Epub 2014 Jan 22.

Weill Cornell Medical College (R.R.F.), Memorial Sloan-Kettering Cancer Center (A.D.Z.), the Department of Medicine, and Columbia University Medical Center (N.L.) - all in New York; U.S. Oncology Research, Springfield, OR (J.P.S.); Stanford University School of Medicine, Stanford (S.E.C.), and Gilead Sciences, Foster City (M.A., D.M.J., L.L.M., D.L., T.M.J., R.D.D.) - both in California; Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC (B.D.C.); Fred Hutchinson Cancer Research Center, University of Washington, Seattle (J.M.P.); St. James's University Hospital, Leeds (P.H.), and Royal Liverpool University Hospital, Liverpool (A.R.P.) - both in the United Kingdom; Hofstra North Shore-LIJ School of Medicine, New Hyde Park, New York (J.C.B.); University of California San Diego, Moores Cancer Center, La Jolla (T.J.K.); Sarah Cannon Research Institute, Nashville (I.F.); Universita Vita-Salute San Raffaele, Instituto Scientifico San Raffaele, Milan (P.G.); David Geffen School of Medicine, University of California Los Angeles, Los Angeles (H.E.); Florida Cancer Specialists, Englewood (T.E.); Centre Hospitalier Lyon-Sud, Pierre-Bénite, France (B.C.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (S.M.); University of Ulm, Ulm (S.S.), and University of Cologne, Cologne (P.C., M.H.) - both in Germany; and University of Texas M.D. Anderson Cancer Center, Houston (S.M.O.).

View Article
March 2014

Chemokine unresponsiveness of chronic lymphocytic leukemia cells results from impaired endosomal recycling of Rap1 and is associated with a distinctive type of immunological anergy.

J Immunol 2013 Aug 26;191(3):1496-504. Epub 2013 Jun 26.

Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3GA, United Kingdom.

View Article
August 2013

Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p.

Eur J Haematol 2011 Oct 11;87(4):372-5. Epub 2011 Aug 11.

Directorate of Clinical Haematology, Royal Liverpool & Broadgreen University Hospitals NHS Trust, Liverpool, UK.

View Article
October 2011

Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition.

Haematologica 2010 Jan 27;95(1):110-8. Epub 2009 Aug 27.

Division of Hematology, School of Cancer Studies, University of Liverpool, 3 Floor Duncan Building, Daulby Street, Liverpool L69 3GA, UK.

View Article
January 2010

Glucocorticoid-based combination therapy for chronic lymphotic leukemia: new tricks for an old dog.

Authors:
Andrew R Pettitt

Leuk Lymphoma 2008 Oct;49(10):1843-5

Division of Haemotology, University of Liverpool School of Cancer Studies, Royal Liverpool University Hospital, Liverpool, UK.

View Article
October 2008

Basic fibroblast growth factor suppresses p53 activation in the neoplastic cells of a proportion of patients with chronic lymphocytic leukaemia.

Oncogene 2005 Oct;24(45):6855-60

Department of Haematology, Royal Liverpool University Hospital, Level 2 Ducan Building, Prescot Street, Liverpool, Merseyside L7 8XP, UK.

View Article
October 2005

The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes.

Oncogene 2004 Mar;23(10):1911-21

Department of Haematology, Royal Liverpool University Hospital, Prescot Street, Liverpool L7 8XP, UK.

View Article
March 2004

Mechanism of action of purine analogues in chronic lymphocytic leukaemia.

Authors:
Andrew R Pettitt

Br J Haematol 2003 Jun;121(5):692-702

Department of Haematology, Royal Liverpool University Hospital, Liverpool, UK.

View Article
June 2003

Correlation between cell size and CD38 expression in chronic lymphocytic leukaemia.

Leuk Lymphoma 2003 May;44(5):797-800

Department of Haematology, Level 2 Duncan Building, Royal Liverpool University Hospital, Liverpool L7 8XP, UK.

View Article
May 2003

Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia.

Blood 2002 Aug;100(4):1404-9

Department of Haematology, Royal Liverpool University Hospital, United Kingdom.

View Article
August 2002

Cytoprotective antioxidant activity of serum albumin and autocrine catalase in chronic lymphocytic leukaemia.

Br J Haematol 2002 Feb;116(2):316-28

Department of Haematology, Royal Liverpool University Hospital, Liverpool, UK.

View Article
February 2002